IPP Bureau
Kokilaben Dhirubhai Ambani Hospital makes history with India’s first intercontinental remote robotic surgeries
By IPP Bureau - December 31, 2025
The Toumai platform, currently the only robotic system with US FDA Study Approval for telesurgery, enabled real-time surgical control with no compromise to patient safety
Cupid to set up FMCG manufacturing facility in Saudi Arabia
By IPP Bureau - December 30, 2025
The plant is expected to enhance regional supply capabilities
Astal signs LoI with Immuna Therapeutics
By IPP Bureau - December 30, 2025
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
ABL Bio secures $55 million from Eli Lilly to accelerate Grabody platform development
By IPP Bureau - December 30, 2025
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
One jab, six months: Leuprolide mesylate shows strong efficacy in children with precocious puberty
By IPP Bureau - December 30, 2025
The study met its primary endpoint with flying colors
Italfarmaco and JCR Pharmaceuticals partner to bring Duchenne therapy to Japan
By IPP Bureau - December 30, 2025
The partnership also sets the stage for broader collaboration on rare disease treatments
Chennai's VS Hospitals introduce cutting-edge brain therapy with TMS
By IPP Bureau - December 30, 2025
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
Biohaven reports Phase 2 depression trial results
By IPP Bureau - December 30, 2025
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
Edgewise Therapeutics reports positive updates from HCM drug EDG-7500
By IPP Bureau - December 30, 2025
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
INOVIO’s DNA therapy for rare throat disease gets FDA review
By IPP Bureau - December 30, 2025
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies
By IPP Bureau - December 30, 2025
Harbour BioMed brings advanced antibody discovery platforms to the table
Senhwa Biosciences launches groundbreaking trial for HER2-positive tumours
By IPP Bureau - December 30, 2025
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
Next Gen Diagnostics to spin off infection prevention unit
By IPP Bureau - December 29, 2025
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Quantum BioPharma completes key toxicity studies for Lucid-MS, paving way for Phase 2 MS trial
By IPP Bureau - December 29, 2025
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
SN Bioscience’s SNB-101 wins FDA orphan drug designation for gastric cancer
By IPP Bureau - December 29, 2025
The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
